P522 Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 Program
Peyrin-Biroulet, L.(1);Siegel, C.(2);Tanida, S.(3);Bossuyt, P.(4);Torres, E.(5);Dubinsky, M.(6);Baert, F.(7);Zhou, W.(8);Klaff, J.(8);Berg, S.(8);Laroux, F.S.(9);Sanchez Gonzalez, Y.(8);Yao, X.(8);Zhou, Q.(8);Reinisch, W.(10);
(1)University Hospital of Nancy, none, Vandoeuvre, France;(2)Dartmouth-Hitchcock Medical Center, none, Lebanon, United States;(3)Naogoya City University Hospital, none, Nagoya, Japan;(4)Imelda General Hospital, none, Bonheiden, Belgium;(5)University of Puerto Rico School of Medicine, none, San Juan, United States;(6)Icahn School of Medicine at Mt Sinai, none, New York City, United States;(7)AZ Delta, none, Roeselare-Menen, Belgium;(8)AbbVie- Inc, none, North Chicago, United States;(9)AbbVie Bioresearch Center, none, Worcester, United States;(10)Medical University of Vienna, none, Vienna, Austria;
Upadacitinib (UPA), an oral selective and reversible JAK inhibitor, demonstrated significantly greater efficacy compared to placebo (PBO) as treatment for moderate to severe ulcerative colitis (UC), in phase 3 induction (U-ACHIEVE and U-ACCOMPLISH) and maintenance (U-ACHIEVE Maintenance) studies. We evaluated UPA efficacy on histologic outcomes with or without endoscopy in this phase 3 program. The STRIDE II initiative identified histological healing as a treatment target signaling the importance of histologic endpoint inclusion in clinical trials and practice.
The UC phase 3 program were multicenter, double-blind PBO-controlled trials. Induction studies enrolled adult patients with moderate to severe active UC (defined as Adapted Mayo Score of 5-9 points and a centrally reviewed endoscopy subscore of 2-3), with randomization 2:1, UPA 45mg (UPA45) once daily (QD) or PBO. Patients eligible for U-ACHIEVE Maintenance primary analysis (N=451) were clinical responders (per Adapted Mayo score) to 8-weeks (wks) of induction treatment with UPA45. U-ACHIEVE Maintenance patients were randomized 1:1:1 UPA 15mg QD (UPA15): UPA 30mg QD (UPA30): PBO for 52 wks. Endpoints were assessed at wk 8 and/or 52: histological improvement, histologic remission, histologic endoscopic mucosal improvement (HEMI), and mucosal healing (a more stringent endpoint defined as endoscopic score=0 and Geboes score<2.0). For endpoint definitions, see Tables 1 and 2.
Baseline characteristics were similar at wk 0 of induction or maintenance studies. In U-ACHIEVE Induction, patients treated with UPA45 demonstrated a significant increase in histologic improvement (55.0% vs 22.5%), HEMI (30.0% vs 6.6%), and mucosal healing (10.7% vs 1.3%); compared to PBO-treated patients (p< 0.001 for all endpoints, Table1). In U-ACCOMPLISH, patients treated with UPA45 experienced superior efficacy in histologic improvement (62.2% vs 24.5%), HEMI (36.7% vs 5.8%), and mucosal healing (13.5% vs 1.7%) compared to PBO-treated patients (p<0.001 for all endpoints). Significantly higher percentages of patients that received UPA15 and UPA30 (42.8% and 56.9%) at wk 52 demonstrated increased histological improvement compared to PBO-treated patients (20.6%; p<0.001). In addition, patients treated with UPA15 and UPA30 demonstrated superior HEMI (UPA15 34.8%; UPA30 49.3%; PBO 11.8%, p<0.001) and mucosal healing rates (UPA15 17.6%; UPA30 19.0%; PBO 4.7%; p<0.001 for both endpoints).
UPA induction and maintenance treatment achieved superior efficacy compared to PBO for all histologic and endoscopic assessments including mucosal healing. [Clinicaltrials.gov, U-ACHIEVE Induction and Maintenance (NCT02819635) and U-ACCOMPLISH (NCT03653026)]